ecteinascidin 743 has been researched along with Uterine Neoplasms in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bergamini, A; Bologna, A; Giolitto, S; Lorusso, D; Mangili, G; Mantero, M; Musacchio, L; Nicoloso, MS; Pignata, S; Pisano, C; Raspagliesi, F; Ronzulli, D; Salutari, V; Scambia, G; Tamberi, S | 1 |
| Jones, RL; Loggers, ET; Pollack, SM; Rodler, ET; Schroeder, BA | 1 |
| Casali, PG; Sanfilippo, R | 1 |
| Alexandre, J; Bertucci, F; Bompas, E; Chevreau, C; Collard, O; Cupissol, D; Delcambre, C; Duffaud, F; Floquet, A; Guillemet, C; Isambert, N; Lacas, B; Lavau-Denes, S; Le Cesne, A; Pautier, P; Penel, N; Piperno-Neumann, S; Selle, F; Soulié, P; Thyss, A; Toulmonde, M | 1 |
| Grignani, G; MartÃn-Broto, J; Reichardt, P; Schuler, M | 1 |
| Amadori, D; Bongiovanni, A; Cavaliere, D; De Vita, A; Ibrahim, T; La Manna, F; Liverani, C; Mercatali, L; Oboldi, D; Pieri, F; Ricci, M; Riva, N; Verdecchia, GM | 1 |
| Kim, HJ; Kim, JW; Kim, M; Lee, KH; Suh, DH | 1 |
| Amunni, G; Lavacchi, D; Mazzei, T; Montelatici, S; Tavella, K; Vannini, L; Villanucci, A | 1 |
| Fader, AN; Ricci, S; Stone, RL | 1 |
| Amant, F; Coosemans, A; Everaert, E; Renard, V; Vergote, I | 1 |
| Corrado, G; Ferrandina, G; Fuoco, G; Lucidi, A; Salutari, V | 1 |
| Ray-Coquard, I | 1 |
| Banerjee, S; Casali, PG; D'Incalci, M; Dei Tos, AP; Grosso, F; Jones, RL; Judson, I; Pilotti, S; Raspagliesi, F; Sanfilippo, R | 1 |
| Blessing, JA; Burke, JJ; Hensley, ML; Monk, BJ; Muller, CY; Street, DG | 1 |
| Cowan, C; Koontz, MZ; Monk, BJ; Saffari, B; Tewari, D; Wallick, AC | 1 |
4 review(s) available for ecteinascidin 743 and Uterine Neoplasms
| Article | Year |
|---|---|
Major clinical research advances in gynecologic cancer in 2015.
Topics: Biomedical Research; Breast Neoplasms; Combined Modality Therapy; Dioxoles; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Papillomavirus Vaccines; Precision Medicine; Tetrahydroisoquinolines; Trabectedin; Uterine Cervical Neoplasms; Uterine Neoplasms | 2016 |
Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Chemotherapy, Adjuvant; Deoxycytidine; Diagnostic Errors; Dioxoles; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Hysterectomy; Indazoles; Laparoscopy; Leiomyoma; Leiomyosarcoma; Morcellation; Neoplasm Staging; Pyrimidines; Sulfonamides; Taxoids; Tetrahydroisoquinolines; Trabectedin; Uterine Myomectomy; Uterine Neoplasms | 2017 |
Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Uterine Neoplasms | 2009 |
An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Female; Humans; Leiomyosarcoma; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2011 |
3 trial(s) available for ecteinascidin 743 and Uterine Neoplasms
| Article | Year |
|---|---|
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Progression-Free Survival; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2022 |
Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Leiomyosarcoma; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2015 |
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2012 |
8 other study(ies) available for ecteinascidin 743 and Uterine Neoplasms
| Article | Year |
|---|---|
Clinical benefit of trabectedin in uterine adenosarcoma.
Topics: Adenosarcoma; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Middle Aged; Prospective Studies; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Uterine Neoplasms | 2013 |
The intriguing patterns of tumor response to trabectedin.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Molecular Targeted Therapy; Sarcoma; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome; Tumor Microenvironment; Uterine Neoplasms | 2013 |
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contraindications; Dacarbazine; Deoxycytidine; Dioxoles; Female; Femoral Neoplasms; Gemcitabine; Humans; Hysterectomy; Ifosfamide; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Thigh; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome; Uterine Neoplasms | 2015 |
Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Leiomyosarcoma; Middle Aged; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Uterine Neoplasms | 2015 |
Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin.
Topics: Aged; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Leiomyosarcoma; Neoplasm Metastasis; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2017 |
Prolonged clinical response to trabectedin in a heavily pretreated patient with advanced uterine leiomyosarcoma: a case report and literature review.
Topics: Dioxoles; Female; Humans; Leiomyosarcoma; Middle Aged; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2011 |
Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dioxoles; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Middle Aged; Retrospective Studies; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2011 |
Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Drug Administration Schedule; Drugs, Investigational; Female; Humans; Leiomyosarcoma; Lung Neoplasms; Neoplasm Recurrence, Local; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2006 |